e-learning
resources
Paris 2018
Sunday, 16.09.2018
Asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma (SAA) after withdrawal of Omalizumab therapy
C. Wang (Taoyuan, Taiwan), C. Lo (Taoyuan, Taiwan), H. Kuo (Taoyuan, Taiwan)
Source:
International Congress 2018 – Asthma management
Session:
Asthma management
Session type:
Poster Discussion
Number:
1694
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Wang (Taoyuan, Taiwan), C. Lo (Taoyuan, Taiwan), H. Kuo (Taoyuan, Taiwan). A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma (SAA) after withdrawal of Omalizumab therapy. 1694
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE)
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Clinical effect of clean air administered directly to the breathing zone (airsonett airshower®) on perennial allergic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 353s
Year: 2007
Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA)
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001
Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Is the asthma control questionnaire (ACQ) usefull during acute moderate to severe (AMS) asthma exacerbations (AE)?
Source: Eur Respir J 2004; 24: Suppl. 48, 591s
Year: 2004
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Safety of bronchial thermoplasty (bt), a novel procedure for severe asthma; positive safety profile in the air2 trial
Source: Annual Congress 2009 - Treatment beyond inhalers
Year: 2009
High or standard initial dose of budesonide to control mild-to-moderate asthma?
Source: Eur Respir J 2001; 17: 856-862
Year: 2001
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting
2
-agonists (LABA) in moderately severe COPD
Source: Annual Congress 2011 - Disease management in specific primary care populations
Year: 2011
The utility of the impulse oscillometry system (IOS) in assessing bronchodilator responsiveness in patients with asthma and allergic rhinitis (AR
Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases
Year: 2010
Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Combination of electronically controlled breathing pattern and improved nebulizer technology for inhaled corticosteroid therapy of severe asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Efficacy and safety of the short term immunotherapy (SIT) in allergic rhinoconjunctivitis (AR)
Source: Eur Respir J 2005; 26: Suppl. 49, 134s
Year: 2005
The profile of poor ICS adherence in uncontrolled moderate to severe asthma.
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept